AMARIN $6.78

down -0.14


24/5/2013 06:24 PM  |  NASDAQ : AMRN  |  Industries : Manufacturing / Pharmaceutical and Medicine Manufacturing
12 Mo. Price Change : -35% - AMRN has underperformed the S&P 500 by 60%

Get Trend Analysis Icon Get Trend Analysis

Partner Headlines

  1. Amarin Announces USPTO Allowance for Application 13/614,129 ...

    Benzinga

  2. Amarin Announces Patent Allowance Related to Vascepa and FDA ...

    Benzinga

  3. Weekly Guru Bargains Highlights: PANL, THRX, ZNGA, LORL, AMRN

    GuruFocus

  4. Benzinga's Top Pre-Market Gainers

    Benzinga

  5. Amarin Completes Dosing in a Fixed-Dose Combination Study With ...

    Benzinga

  6. Amarin Closes Dosing in Fixed-Dose Combination Study with Vascepa

    Benzinga

  7. FDA's Orange Book Doesn't Include Amarin's Vascepa NCE Status in ...

    Benzinga

  8. Benzinga's Top Pre-Market Gainers

    Benzinga

  9. Amarin Receives Patent Allowance for Application 13/623,450 ...

    Benzinga

  10. Amarin Announces David Stack Appointed to Board of Directors

    Benzinga

  11. Amarin Spikes Lower

    Benzinga

  12. UDPATE: Aegis Capital Raises PT on Amarin to $35

    Benzinga

  13. Citigroup Reiterates Buy Rating, $20 PT on Amarin Corporation

    Benzinga

  14. Benzinga's Top Pre-Market Losers

    Benzinga

  15. UPDATE: Citigroup Initiates Amarin at Buy on Vascepa Overhang Removal

    Benzinga

  16. Benzinga's Top Pre-Market Gainers

    Benzinga

  17. Amarin Awarded Patent 8,318,715 for Vascepa by USPTO

    Benzinga

  18. Amarin Announces USPTO has Published Notification of Notice of ...

    Benzinga

  19. A Peek Into The Market Before The Trading Starts

    Benzinga

  20. Amarin Announces US Patent 8,314,086 Award for Vascepa

    Benzinga

  21. Mid-Morning Market Update: Markets Rallying; J.C. Penney Misses ...

    Benzinga

  22. Amarin Awarded US Patent 8,298,554 Issuance for Vascepa

    Benzinga

  23. UPDATE: Wedbush Securities Downgrades Amarin Corporation to ...

    Benzinga

  24. Benzinga's M&A Chatter for Tuesday September 11, 2012

    Benzinga

  25. Benzinga's M&A Chatter for Thursday September 6, 2012

    Benzinga

  26. Amarin Announces Notification of Patent Allowances for U.S. ...

    Benzinga

  27. Amarin Announces Notification of Patent Allowance for Vascepa in US

    Benzinga

  28. Amarin Announces Additional Publication of MARINE Phase 3 Clinical ...

    Benzinga

  29. Health Care Sector Wrap

    FOXBusiness

  30. Benzinga's Top Pre-Market Gainers

    Benzinga

  31. Health Care Sector Wrap

    FOXBusiness

  32. Health Care Sector Wrap

    FOXBusiness

  33. Amarin Corporation (AMRN) Sees Spike in Option Activity with Stock ...

    At Market Intelligence Center

  34. Amarin's

    Investors Business Daily

  35. Facebook Inc. - Class A, Starbucks Among Stocks Down on High ...

    FOXBusiness

  36. Amarin Announces FDA Approval of Vascepa Capsules for the ...

    Benzinga

  37. Amarin and Horizon Pharma Higher Ahead of PDUFA Dates

    Benzinga

  38. Health Care Sector Wrap

    FOXBusiness

  39. Amarin Responds to Erroneous Website Posting

    Benzinga

  40. Biotechs With Upcoming PDUFA Dates

    Benzinga

  41. UPDATE: Aegis Capital Initiates Amarin Corporation with Buy, $25 ...

    Benzinga

  42. New Annual Highs: AMRN, DIS, and NWS

    By SchaeffersResearch

  43. Health Care Sector Wrap

    FOXBusiness

  44. Amarin (AMRN) Gains 10.5% As Company Appears Close to Winning ...

    At Market Intelligence Center

  45. Amarin Corporation plc, Loral Space & Communications Gapping Up ...

    FOXBusiness

  46. UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT for ...

    Benzinga

  47. CF Industries Holdings, SBA Communications Corporation Included in ...

    FOXBusiness

  48. AMR101 Phase 3 Study Data in Patients With Diabetes Mellitus (Type ...

    Benzinga

  49. Amarin Corporation plc (AMRN) Sees Above Average Option Activity ...

    At Market Intelligence Center

  50. Earnings Scheduled For May 8

    Benzinga

  51. Amarin

    at IBD

  52. Amarin (AMRN) Up 20% on Patent News, Analyst Commentary

    At Market Intelligence Center

  53. Amarin Up 7% After FDA Announces it Will Not Convene FDA Panel for ...

    at Benzinga

  54. AMRN said the FDA accepted a new drug for review, while OII ...

    By SchaeffersResearch

  55. Benzinga's M&A Chatter for Tuesday December 6, 2011

    at Benzinga
People viewing AMRN also viewed: , , , , , ,
Marketplace
Trading Center